Abstract
Epidemiologic evidence strongly correlates suppression of maturation of the immune system to incidences of cancer. The effectiveness of chemotherapeutic agents significantly depends upon the ability of the cancer cells to express (costimulatory) molecules on their surface that can be recognized and engaged by their surrogate ligands of the immune system, thereby resulting in immune-directed cell killing. Alterations in the metabolic strategies of cancer cells (such as: the rate of glucose utilization, glucose or fatty acid oxidation, the magnitude of the membrane potential and the pH gradient across the mitochondrial membrane, and/or changes in uncoupling protein levels) can modulate the expression of some cell surface “death receptors"; thereby conferring resistance to certain cell death-inducing stimuli.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Voet D, Voet J. Chapter 22: Electron Transport and Oxidative Phosphorylation. Biochemistry John Wiley & Sons, Inc. (2004).
Bhushan A, et al. Drug resistance results in alterations in expression of immune recognition molecules and failure to express Fas (CD95). Immunol Cell Biol1998; 76:350–356.
Brundtland GH. The Global Burden of Cancer In: Stewart BW, Kleihues P, eds. World cancer report. Lyon: International Agency for Research on Cancer, World Health Organization, 2003:352.
Marrack P, Kappler J. The T cell receptor. Science 1987; 238:1073–1079.
Bretscher PA, Cohn M. A theory of self-nonself discrimination. Science 1970; 169: 1042–1049.
Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Ann Rev Immunol 1993; 11:191–212.
Linsley PS, et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA4. Immunity 1994; 1:793–801.
June CH, et al. The B7 and CD28 receptor families. Immunol Today 1994; 15:321–330.
Kuchroo VK, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80: 707–718.
Lanier LL, et al. CD80(B7) and CD86(B70) provide similiar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol 1995; 154: 97–105.
Alderson MR, et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993; 178:2231–2235.
Nagata S, Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model. J Hum Genet 1998; 43(1):2–8.
Desbarats J, et al. Dichotomy between naïve and memory CD4+ T cell responses to Fas (CD95) engagement. Proc Natl Acad Sci USA 1999; 96:8104–8109.
Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000; 6(8):920–923.
Mavligit GM, et al. Cell-mediated immunity to human solid tumors: in vitro detection by lymphocyte blastogenic responses to cell-associated and solubilized tumor antigens. Natl Cancer Inst Monogr 1973; 37:167–176.
Whelan M, et al. Cancer immunotherapy: an embarrassment of riches? Drug Discov Today 2003; 8(6):253–258.
Martindale D. T cell triumph: immunotherapy may have finally turned a corner. Sci Am 2003; 288(2):18–19.
Tsuruo T, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003; 94(1):15–21.
Newell MK, et al. Does the oxidative/glycolytic ratio determine proliferation or death in immune recognition? Ann NY Acad Sci 1999; 887:77–82.
Nagata S, Golstein P. The Fas death factor. Science 1995; 267:1449–1456.
Nagata S. Apoptosis by death factor. Cell 1997; 88:355–365.
Schneider P, Tschopp J. Apoptosis induced by death receptors. Pharm Acta Helv 2000; 74(2–3):281–286.
Kataoka T, et al. Expression level of c-FLIP versus Fas determines susceptibility to Fas ligand-induced cell death in murine thymoma EL-4 cells. Exp Cell Res 2002; 273(2):256–264.
Harper M-E, et al. Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J 2002;16(12):1550–1557.
Sinkovics JG, Horvath JC. Virological and immunological connotations of apoptotic and anti-apoptotic forces in neoplasia. Int J Oncol 2001; 19(3):473–488.
Green DR, Evan GI. A matter of life and death. Cancer Cell 2002; 1(1):19–30.
Tolomeo M, Simoni D. Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies. Curr Med Chem Anti-Cancer Agents 2002; 2(3):387–401.
Landowski TH, et al. Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. Blood 1999; 94(1):265–274.
Venditti JM, Sheldon DR, Goldin A. Evaluation of antileukemic agents employing advanced leukemia L1210 in mice. VII. Cancer Res 1964; 24(1 Pt 1):145–210.
Villalobos-Menuey EM. Metabolic regulation of the cellular distribution and function of Fas (CD95). Master’s thesis, University of Colorado, Colorado Springs, 2001:1–83.
Newell MK, Melamede RJ, Villalobos-Menuey E, Swartzendruber D, Trauger R, Camley RE, Crisp W. The effects of chemotherapeutics on cellular metabolism and consequent immune recognition. J Immune Based Ther Vaccines 2004; 2(1):3.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Newell, M.K., Villalobos-Menuey, E.M., Burnett, M., Camley, R.E. (2009). Uncoupling Cellular Respiration: A Link to Cancer Cell Metabolism and Immune Privilege. In: Sarangarajan, R., Apte, S. (eds) Cellular Respiration and Carcinogenesis. Humana Press. https://doi.org/10.1007/978-1-59745-435-3_11
Download citation
DOI: https://doi.org/10.1007/978-1-59745-435-3_11
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-934115-07-7
Online ISBN: 978-1-59745-435-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)